[
  {
    "ts": null,
    "headline": "Merck's $2 Billion Bet: The Tiny Biotech That Could Save Its Neurology Pipeline",
    "summary": "Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.",
    "url": "https://finnhub.io/api/news?id=41dc742014509057581f09f071f55ef818b0de9e1cd3eb9dc16715f593a6a7af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755552031,
      "headline": "Merck's $2 Billion Bet: The Tiny Biotech That Could Save Its Neurology Pipeline",
      "id": 136416977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.",
      "url": "https://finnhub.io/api/news?id=41dc742014509057581f09f071f55ef818b0de9e1cd3eb9dc16715f593a6a7af"
    }
  },
  {
    "ts": null,
    "headline": "GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?",
    "summary": "Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.",
    "url": "https://finnhub.io/api/news?id=b8482983c963df7f0c93e9cb3d420c5bddee687775533af29852e7d35cb9deff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755523500,
      "headline": "GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?",
      "id": 136408495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.",
      "url": "https://finnhub.io/api/news?id=b8482983c963df7f0c93e9cb3d420c5bddee687775533af29852e7d35cb9deff"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors",
    "summary": "OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the",
    "url": "https://finnhub.io/api/news?id=3f315ffb0b63c449b75380f1d14b17f810fb1ea6250e3c5b67d2b4969cf022fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755523380,
      "headline": "European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors",
      "id": 136408496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the",
      "url": "https://finnhub.io/api/news?id=3f315ffb0b63c449b75380f1d14b17f810fb1ea6250e3c5b67d2b4969cf022fe"
    }
  },
  {
    "ts": null,
    "headline": "Macquarie Growth And Income Fund Q1 2025 Commentary",
    "summary": "For 2Q25, Macquarie Growth and Income Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 1000Â® Value Index.",
    "url": "https://finnhub.io/api/news?id=06a97919fbe7ae2f8b32cc1dcd6e9b0ae935a9133dfb5580bc45e6eda5be2045",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755519780,
      "headline": "Macquarie Growth And Income Fund Q1 2025 Commentary",
      "id": 136407703,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190009797/image_2190009797.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "For 2Q25, Macquarie Growth and Income Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 1000Â® Value Index.",
      "url": "https://finnhub.io/api/news?id=06a97919fbe7ae2f8b32cc1dcd6e9b0ae935a9133dfb5580bc45e6eda5be2045"
    }
  },
  {
    "ts": null,
    "headline": "Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer",
    "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., August 18, 2025--Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.",
    "url": "https://finnhub.io/api/news?id=408ed3fba5772c2056d0e80d75cc62ab1b4438362dfa84deb078c8e42e2a66ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755514800,
      "headline": "Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer",
      "id": 136408497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., August 18, 2025--Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.",
      "url": "https://finnhub.io/api/news?id=408ed3fba5772c2056d0e80d75cc62ab1b4438362dfa84deb078c8e42e2a66ec"
    }
  },
  {
    "ts": null,
    "headline": "Biopharma layoffs rise as drugmakers tighten belts and reorganize",
    "summary": "Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.",
    "url": "https://finnhub.io/api/news?id=fa88c71760b7feca0edda9fb50b38c77ec15f2f2a7db74b89a3e4af089ec1731",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755503918,
      "headline": "Biopharma layoffs rise as drugmakers tighten belts and reorganize",
      "id": 136408498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.",
      "url": "https://finnhub.io/api/news?id=fa88c71760b7feca0edda9fb50b38c77ec15f2f2a7db74b89a3e4af089ec1731"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target",
    "summary": "Merckâs strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns. See why MRK stock is a buy.",
    "url": "https://finnhub.io/api/news?id=d4b681f5ab474098dd536dda7e5b680a77549aeee68fb07b8d8a6db34b9de847",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755501535,
      "headline": "Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target",
      "id": 136406543,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merckâs strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns. See why MRK stock is a buy.",
      "url": "https://finnhub.io/api/news?id=d4b681f5ab474098dd536dda7e5b680a77549aeee68fb07b8d8a6db34b9de847"
    }
  },
  {
    "ts": null,
    "headline": "Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration",
    "summary": "Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential. On August 5, Janux Therapeutics announced a clinical milestone in its collaboration with Merck & Co. Inc. (NYSE:MRK), with the first patient being dosed in a lead program from their partnership. This achievement triggered a $10 million milestone payment […]",
    "url": "https://finnhub.io/api/news?id=c962efa290ac59c244b4fc7a9864d42028f97472afc6a2eb2f1a7ff70744d845",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755488461,
      "headline": "Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration",
      "id": 136407186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential. On August 5, Janux Therapeutics announced a clinical milestone in its collaboration with Merck & Co. Inc. (NYSE:MRK), with the first patient being dosed in a lead program from their partnership. This achievement triggered a $10 million milestone payment […]",
      "url": "https://finnhub.io/api/news?id=c962efa290ac59c244b4fc7a9864d42028f97472afc6a2eb2f1a7ff70744d845"
    }
  }
]